Tyra Biosciences Inc To Discuss 300 First Patient Dosed Call Transcript
Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Tyra Biosciences' conference call to discuss the first patient dosed with TYRA-300 and the SURF301 study. As a reminder, this conference is being recorded.
Now I'd like to turn the conference call over to Amy Conrad from Investor Relations. Please proceed.
Thank you, Jamie. Good morning, everyone, and thank you for joining us. With me today from Tyra are Todd Harris, Chief Executive Officer; and Hiroomi Tada, our Chief Medical Officer. Also on today's call is Dr. Jonathan Rosenberg, Chief of the Genitourinary Medical Oncology Service, Division of Solid Tumor Oncology and the Enno W. Ercklentz Chair of Memorial Sloan Kettering Cancer Center.
For those of you participating via conference call, the slides are made available via webcast and can also be accessed by going to the Investor Relations page of our website following conclusion of today's call.
Todd will provide introductory remarks and will review the outsized market opportunity for TYRA-300 and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
